| Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer (NCT05509699) | Hutchison Medipharma Limited | 2022-09-27 |
| A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers (NCT05318820) | Hutchison Medipharma Limited | 2022-06-01 |
| A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors (NCT05173142) | Hutchison Medipharma Limited | 2022-01-22 |
| Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT (NCT05277454) | Hutchison Medipharma Limited | 2022-01-18 |
| Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification (NCT05015608) | Hutchison Medipharma Limited | 2021-11-22 |
| Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC (NCT05009836) | Hutchison Medipharma Limited | 2021-09-06 |
| Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients (NCT04923945) | Hutchison Medipharma Limited | 2021-08-19 |
| Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients (NCT04923932) | Hutchison Medipharma Limited | 2021-07-27 |
| Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma (NCT04849351) | Hutchison Medipharma Limited | 2021-04-15 |
| Surufatinib Hepatic Impairment Study (NCT04755075) | Hutchison Medipharma Limited | 2021-02-12 |
| Surufatinib Renal Impairment Study (NCT04755088) | Hutchison Medipharma Limited | 2021-02-12 |
| Fruquintinib Food Effect and Proton Pump Inhibitor Study (NCT04645940) | Hutchison Medipharma Limited | 2020-09-24 |
| Fruquintinib CYP3A Inhibitor and Inducer Study (NCT04557397) | Hutchison Medipharma Limited | 2020-09-02 |
| A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects (NCT04372394) | Hutchison Medipharma Limited | 2020-08-14 |
| A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer (NCT04322539) | Hutchison Medipharma Limited | 2020-08-12 |
| Surufatinib DDI With a PPI and a CYP3A Inducer (NCT04510649) | Hutchison Medipharma Limited | 2020-07-09 |
| A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects (NCT04372407) | Hutchison Medipharma Limited | 2020-07-09 |
| HMPL-453 in Advanced Malignant Mesothelioma (NCT04290325) | Hutchison Medipharma Limited | 2019-12-30 |
| Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors (NCT04169672) | Hutchison Medipharma Limited | 2019-12-26 |
| The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients (NCT03951623) | Hutchison Medipharma Limited | 2019-08-12 |
| A Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets in Healthy Chinese Male Volunteers (NCT03860948) | Hutchison Medipharma Limited | 2019-04-16 |
| A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients (NCT03873532) | Hutchison Medipharma Limited | 2018-07-10 |
| Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC (NCT03684967) | Hutchison Medipharma Limited | 2018-05-08 |
| To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers (NCT03483259) | Hutchison Medipharma Limited | 2018-04-02 |
| A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion of [14C]Sulfatinib (NCT03627520) | Hutchison Medipharma Limited | 2018-04-02 |
| HMPL-813 in Treating Patients With Glioblastoma (NCT03231501) | Hutchison Medipharma Limited | 2018-01-26 |
| A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers (NCT03251378) | Hutchison Medipharma Limited | 2017-12-11 |
| A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA) (NCT03223376) | Hutchison Medipharma Limited | 2017-10-18 |